- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07795164
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH (PERFORMA)
A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Shaheen Tomah, MD
- Telefonnummer: 240-235-0145
- E-post: performa@altimmune.com
Studiesteder
-
-
Alabama
-
Dothan, Alabama, Forente stater, 36301
- Rekruttering
- Altimmune Clinical Study Site
-
-
Arizona
-
Chandler, Arizona, Forente stater, 85224
- Rekruttering
- Altimmune Clinical Study Site
-
Tucson, Arizona, Forente stater, 85712
- Rekruttering
- Altimmune Clinical Study Site
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- Rekruttering
- Altimmune Clinical Study Site
-
North Little Rock, Arkansas, Forente stater, 72117
- Rekruttering
- Altimmune Clinical Study Site
-
-
California
-
Fountain Valley, California, Forente stater, 92708
- Rekruttering
- Altimmune Clinical Study Site
-
Fresno, California, Forente stater, 93720
- Rekruttering
- Altimmune Clinical Study Site
-
Gardena, California, Forente stater, 90247
- Rekruttering
- Altimmune Clinical Study Site
-
Huntington Park, California, Forente stater, 90255
- Rekruttering
- Altimmune Clinical Study Site
-
La Mesa, California, Forente stater, 91942
- Rekruttering
- Altimmune Clinical Study Site
-
Long Beach, California, Forente stater, 90815
- Rekruttering
- Altimmune Clinical Study Site
-
Orange, California, Forente stater, 92866
- Rekruttering
- Altimmune Clinical Study Site
-
Orange, California, Forente stater, 92868
- Rekruttering
- Altimmune Clinical Study Site
-
Poway, California, Forente stater, 92064
- Rekruttering
- Altimmune Clinical Study Site
-
Van Nuys, California, Forente stater, 91405
- Rekruttering
- Altimmune Clinical Study Site
-
-
Colorado
-
Englewood, Colorado, Forente stater, 80113
- Rekruttering
- Altimmune Clinical Study Site
-
-
Florida
-
Boca Raton, Florida, Forente stater, 33434
- Rekruttering
- Altimmune Clinical Study Site
-
Bradenton, Florida, Forente stater, 34209
- Rekruttering
- Altimmune Clinical Study Site
-
Miami, Florida, Forente stater, 33173
- Rekruttering
- Altimmune Clinical Study Site
-
Miami, Florida, Forente stater, 33122
- Rekruttering
- Altimmune Clinical Study Site
-
Miami Lakes, Florida, Forente stater, 33016
- Rekruttering
- Altimmune Clinical Study Site
-
Ocala, Florida, Forente stater, 34471
- Rekruttering
- Altimmune Clinical Study Site
-
Orlando, Florida, Forente stater, 32803
- Rekruttering
- Altimmune Clinical Study Site
-
Port Orange, Florida, Forente stater, 32127
- Rekruttering
- Altimmune Clinical Study Site
-
-
Georgia
-
Dalton, Georgia, Forente stater, 30720
- Rekruttering
- Altimmune Clinical Study Site
-
-
Indiana
-
South Bend, Indiana, Forente stater, 46635
- Rekruttering
- Altimmune Clinical Study Site
-
-
Louisiana
-
Bastrop, Louisiana, Forente stater, 71220
- Rekruttering
- Altimmune Clinical Study Site
-
Marrero, Louisiana, Forente stater, 70072
- Rekruttering
- Altimmune Clinical Study Site
-
Monroe, Louisiana, Forente stater, 71201
- Rekruttering
- Altimmune Clinical Study Site
-
-
Maryland
-
Laurel, Maryland, Forente stater, 20708
- Rekruttering
- Altimmune Clinical Study Site
-
-
Massachusetts
-
New Bedford, Massachusetts, Forente stater, 02740
- Rekruttering
- Altimmune Clinical Study Site
-
-
Missouri
-
Columbia, Missouri, Forente stater, 65201
- Rekruttering
- Altimmune Clinical Study Site
-
Kansas City, Missouri, Forente stater, 64131
- Rekruttering
- Altimmune Clinical Study Site
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87107
- Rekruttering
- Altimmune Clinical Study Site
-
-
North Carolina
-
Fayetteville, North Carolina, Forente stater, 28304
- Rekruttering
- Altimmune Clinical Study Site
-
-
Ohio
-
Brooklyn, Ohio, Forente stater, 44144
- Rekruttering
- Altimmune Clinical Study Site
-
Springboro, Ohio, Forente stater, 45066
- Rekruttering
- Altimmune Clinical Study Site
-
Westlake, Ohio, Forente stater, 44145
- Rekruttering
- Altimmune Clinical Study Site
-
-
Rhode Island
-
East Greenwich, Rhode Island, Forente stater, 02818
- Rekruttering
- Altimmune Clinical Study Site
-
-
Texas
-
Austin, Texas, Forente stater, 78757
- Rekruttering
- Altimmune Clinical Study Site
-
Bellaire, Texas, Forente stater, 77401
- Rekruttering
- Altimmune Clinical Study Site
-
Brownsville, Texas, Forente stater, 78520
- Rekruttering
- Altimmune Clinical Study Site
-
Corpus Christi, Texas, Forente stater, 78404
- Rekruttering
- Altimmune Clinical Study Site
-
Dallas, Texas, Forente stater, 75230
- Rekruttering
- Altimmune Clinical Study Site
-
Edinburg, Texas, Forente stater, 78539
- Rekruttering
- Altimmune Clinical Study Site
-
Farmers Branch, Texas, Forente stater, 75234
- Rekruttering
- Altimmune Clinical Study Site
-
Forney, Texas, Forente stater, 75126
- Rekruttering
- Altimmune Clinical Study Site
-
Fort Worth, Texas, Forente stater, 76104
- Rekruttering
- Altimmune Clinical Study Site
-
Georgetown, Texas, Forente stater, 78626
- Rekruttering
- Altimmune Clinical Study Site
-
Houston, Texas, Forente stater, 77004
- Rekruttering
- Altimmune Clinical Study Site
-
Houston, Texas, Forente stater, 77079
- Rekruttering
- Altimmune Clinical Study Site
-
Kingwood, Texas, Forente stater, 77339
- Rekruttering
- Altimmune Clinical Study Site
-
Pasadena, Texas, Forente stater, 77505
- Rekruttering
- Altimmune Clinical Study Site
-
San Antonio, Texas, Forente stater, 78215
- Rekruttering
- Altimmune Clinical Study Site
-
San Antonio, Texas, Forente stater, 78209
- Rekruttering
- Altimmune Clinical Study Site
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- Altimmune Clinical Study Site
-
Sugar Land, Texas, Forente stater, 77479
- Rekruttering
- Altimmune Clinical Study Site
-
Waco, Texas, Forente stater, 76710
- Rekruttering
- Altimmune Clinical Study Site
-
-
Utah
-
Ogden, Utah, Forente stater, 84405
- Rekruttering
- Altimmune Clinical Study Site
-
West Jordan, Utah, Forente stater, 84088
- Rekruttering
- Altimmune Clinical Study Site
-
-
Washington
-
Seattle, Washington, Forente stater, 98105
- Rekruttering
- Altimmune Clinical Study Site
-
-
-
-
Puerto Rico
-
San Juan, Puerto Rico, Puerto Rico, 00927
- Rekruttering
- Altimmune Clinical Study Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
All subjects:
- No significant changes in body weight (±5%) and not participating in a structured weight loss program for the 3 months prior to screening (or since the historical biopsy, if applicable)
- Body mass index (BMI) ≥ 25.0 kg/m2; if Asian, BMI ≥ 23.0 kg/m2
- Type 2 diabetes (T2D) or at least 2 components of metabolic syndrome
- Subject agrees to have liver biopsy(ies) as required per protocol
Cohort 1 - Histologic diagnosis of F2/F3 MASH based on liver biopsy during screening or historical biopsy within 6 months before screening
Cohort 2 - Presumed F2/F3 MASH based on noninvasive testing
Exclusion Criteria:
- Cirrhosis (F4); portal hypertension or hepatic decompensation; acute or chronic liver disease other than MASH; liver function tests (ALT, AST; alkaline phosphatase; total bilirubin; INR; and platelet count) outside of acceptable ranges; positive HBsAg; active hepatitis C
- Uncontrolled T2D or clinically significant persistent hyperglycemia
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Placebo SC Injection |
|
Eksperimentell: Pemvidutid 2,4 mg
|
Pemvidutide SC Injection |
|
Eksperimentell: Pemvidutide 1.8 mg
|
Pemvidutide SC Injection |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical Outcome Event
Tidsramme: Baseline through end of study (approximately Month 60)
|
Time to first occurrence of any of the following events through the end of the study: Histologic progression to cirrhosis (F4) on liver biopsy; Liver related events; Liver transplantation; or Death due to any cause |
Baseline through end of study (approximately Month 60)
|
|
Histological Response: MASH resolution
Tidsramme: Baseline through Week 52
|
Proportion of subjects achieving MASH resolution (according to NASH Clinical Research Network [CRN] classification) without worsening of fibrosis |
Baseline through Week 52
|
|
Histological Response: Fibrosis improvement
Tidsramme: Baseline through Week 52
|
Proportion of subjects achieving ≥ 1 stage improvement in liver fibrosis according to the NASH CRN fibrosis staging system without worsening of MASH |
Baseline through Week 52
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Histologic Response: Proportion of subjects achieving both MASH resolution (according to NASH CRN classification) without worsening of fibrosis and ≥ 1 stage improvement in liver fibrosis without worsening of MASH
Tidsramme: Baseline through Week 52
|
Baseline through Week 52
|
|
HistoIndex qFibrosis: Proportion of subjects with at least a 1 stage improvement in qFibrosis
Tidsramme: Baseline through Week 52
|
Baseline through Week 52
|
|
Anthropometric parameters: Relative (%) change from baseline in body weight (kg)
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in body mass index (BMI; kg/m2)
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in waist circumference (cm)
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in alanine aminotransferase (ALT; U/L)
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in enhanced liver fibrosis (ELF) score
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Relative (%) change from baseline in vibration controlled transient elastography (VCTE; kPa) by Fibroscan
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in core symptoms of MASH on the NASH-CHECK questionnaire.
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Short-form 36 (SF-36) summary scores.
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) domain scores.
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- ALT-801-301
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .